Primary and Secondary Endpoints Are Met
Acadia Phaemaceuticals announced successful top-line results for the Phase III trial of its Pimavanserin drug for patients with Parkinson’s disease psychosis. The compound met the primary endpoint by demonstrating highly significant antipsychotic efficacy using a nine-item scale. It also met a secondary endpoint for motoric tolerability. ACAD is up 160 percent before the bell on my tradeMONSTER platform!
Ralcorp Accepts ConAgra Takeover Offer
Ralcorp agreed to be purchased by ConAgra for $90 a share in cash. That's a nice premium for RAH, which closed at $70.23 yesterday, and the stock is up almost 27 percent in early trading.
Las Vegas Sands Rallies on Special Dividend
Las Vegas Sands announced that its board approved a special dividend of $2.75 a share in cash. LVS climbs more than 4 percent in the premarket.
More From optionMONSTER